The impact of perfectionism on treatment outcomes of mental health disorders: a systematic review of randomised controlled trials.

Cogn Behav TherAug 26, 2025 (epub)
Clinical ResearchPsychiatry

Zhaohong Jiang, Sarah J Egan, Danyelle Greene et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined whether perfectionism predicts treatment outcomes in randomised controlled trials of mental health disorders. It included 16 trials with 2,197 participants; 15 assessed the association between baseline perfectionism and primary disorder outcomes across eating, anxiety, obsessive-compulsive, depressive, and body dysmorphic disorders. Nine of those 15 studies (56%) linked higher baseline perfectionism with poorer outcomes, five (38%) found no significant association, and one (6%) reported mixed findings. Overall, results were mixed, with negative associations reported in several studies.

Key findings

  • Nine of 15 studies (56%) found higher baseline perfectionism associated with poorer treatment outcomes.
  • Five of 15 studies (38%) found no significant association; one (6%) reported mixed findings.
  • Four out of five studies involving children and adolescents reported negative impacts of baseline perfectionism.

Why it matters

The review suggests perfectionism may be relevant to treatment progress for some people, but its prognostic value is not consistent across disorders or studies. Recognising this variability can help clinicians consider perfectionism as a possible factor when outcomes are limited, without assuming it predicts response for every patient.

What to keep in mind

Some included studies had high risk of bias, and the review did not conduct meta-analyses.

Source

Published in Cogn Behav Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.